SynthesisFrontiers in microbiology2026
Relationship between small intestinal bacterial overgrowth and irritable bowel syndrome and the efficacy of rifaximin intervention: a systematic review and meta-analysis.
Synthesis in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically investigate the pooled prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in patients with Irritable Bowel Syndrome (IBS) compared to healthy individuals and to evaluate the therapeutic efficacy of rifaximin in IBS patients with concomitant SIBO. Methods: A comprehensive computer-based search was conducted across databases including PubMed and Embase from their inception until December 2025. Relevant cohort studies, case-control studies, and cross-sectional studies were included. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). Meta-analysis was performed using a random-effects model. Results: A total of 25 studies were included. The pooled risk of SIBO was significantly higher in IBS patients compared to healthy controls (OR = 5.71, 95% CI: 3.45-9.45). The Glucose Hydrogen Breath Test (GBT) subgroup showed a higher odds ratio and lower heterogeneity. Rifaximin treatment achieved a pooled SIBO eradication rate of 59% (95% CI: 0.48-0.68), with the medium-to-high dose group (≥ 1,200 mg/day) showing a slightly superior efficacy compared to the lower-dose group. Conclusion: A significant association exists between SIBO and IBS. Rifaximin is an effective treatment for IBS patients with concomitant SIBO. The substrate choice for SIBO diagnosis involves a trade-off: while GBT offers greater diagnostic stability and specificity, LBT provides broader sensitivity for distal overgrowth. This evidence-based nuance should guide clinical substrate selection based on the diagnostic priority. Systematic review registration: INPLASY.COM, identifier NPLASY202630002.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.